Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector

The global outbreak of COVID-19 has caused a severe threat to human health; therefore, simple, high-throughput neutralization assays are desirable for developing vaccines and drugs against COVID-19. In this study, a high-titre SARS-CoV-2 pseudovirus was successfully packaged by truncating the C-term...

Full description

Saved in:
Bibliographic Details
Main Authors: Ziteng Liang, Xi Wu, Jiajing Wu, Shuo Liu, Jincheng Tong, Tao Li, Yuanling Yu, Li Zhang, Chenyan Zhao, Qiong Lu, Haiyang Qin, Jianhui Nie, Weijin Huang, Youchun Wang
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Emerging Microbes and Infections
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2023.2261566
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849423339786862592
author Ziteng Liang
Xi Wu
Jiajing Wu
Shuo Liu
Jincheng Tong
Tao Li
Yuanling Yu
Li Zhang
Chenyan Zhao
Qiong Lu
Haiyang Qin
Jianhui Nie
Weijin Huang
Youchun Wang
author_facet Ziteng Liang
Xi Wu
Jiajing Wu
Shuo Liu
Jincheng Tong
Tao Li
Yuanling Yu
Li Zhang
Chenyan Zhao
Qiong Lu
Haiyang Qin
Jianhui Nie
Weijin Huang
Youchun Wang
author_sort Ziteng Liang
collection DOAJ
description The global outbreak of COVID-19 has caused a severe threat to human health; therefore, simple, high-throughput neutralization assays are desirable for developing vaccines and drugs against COVID-19. In this study, a high-titre SARS-CoV-2 pseudovirus was successfully packaged by truncating the C-terminus of the SARS-CoV-2 spike protein by 21 amino acids and infecting 293 T cells that had been stably transfected with the angiotensin-converting enzyme 2 (ACE2) receptor and furin (named AF cells), to establish a simple, high-throughput, and automated 384-well plate neutralization assay. The method was optimized for cell amount, virus inoculation, incubation time, and detection time. The automated assay showed good sensitivity, accuracy, reproducibility, Z’ factor, and a good correlation with the live virus neutralization assay. The high-throughput approach would make it available for the SARS-CoV-2 neutralization test in large-scale clinical trials and seroepidemiological surveys which would aid the accelerated vaccine development and evaluation.
format Article
id doaj-art-a18edf92a2004e7184b7de3511f620fb
institution Kabale University
issn 2222-1751
language English
publishDate 2023-12-01
publisher Taylor & Francis Group
record_format Article
series Emerging Microbes and Infections
spelling doaj-art-a18edf92a2004e7184b7de3511f620fb2025-08-20T03:30:37ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512023-12-0112210.1080/22221751.2023.2261566Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vectorZiteng Liang0Xi Wu1Jiajing Wu2Shuo Liu3Jincheng Tong4Tao Li5Yuanling Yu6Li Zhang7Chenyan Zhao8Qiong Lu9Haiyang Qin10Jianhui Nie11Weijin Huang12Youchun Wang13Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People’s Republic of ChinaBeijing Yunling Biotechnology Co., Ltd., Beijing, People’s Republic of ChinaChangping Laboratory, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People’s Republic of ChinaChangping Laboratory, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People’s Republic of ChinaThe global outbreak of COVID-19 has caused a severe threat to human health; therefore, simple, high-throughput neutralization assays are desirable for developing vaccines and drugs against COVID-19. In this study, a high-titre SARS-CoV-2 pseudovirus was successfully packaged by truncating the C-terminus of the SARS-CoV-2 spike protein by 21 amino acids and infecting 293 T cells that had been stably transfected with the angiotensin-converting enzyme 2 (ACE2) receptor and furin (named AF cells), to establish a simple, high-throughput, and automated 384-well plate neutralization assay. The method was optimized for cell amount, virus inoculation, incubation time, and detection time. The automated assay showed good sensitivity, accuracy, reproducibility, Z’ factor, and a good correlation with the live virus neutralization assay. The high-throughput approach would make it available for the SARS-CoV-2 neutralization test in large-scale clinical trials and seroepidemiological surveys which would aid the accelerated vaccine development and evaluation.https://www.tandfonline.com/doi/10.1080/22221751.2023.2261566SARS-CoV-2VSVpseudovirusneutralization assayhigh-throughput
spellingShingle Ziteng Liang
Xi Wu
Jiajing Wu
Shuo Liu
Jincheng Tong
Tao Li
Yuanling Yu
Li Zhang
Chenyan Zhao
Qiong Lu
Haiyang Qin
Jianhui Nie
Weijin Huang
Youchun Wang
Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
Emerging Microbes and Infections
SARS-CoV-2
VSV
pseudovirus
neutralization assay
high-throughput
title Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
title_full Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
title_fullStr Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
title_full_unstemmed Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
title_short Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
title_sort development of an automated high throughput sars cov 2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus vsv vector
topic SARS-CoV-2
VSV
pseudovirus
neutralization assay
high-throughput
url https://www.tandfonline.com/doi/10.1080/22221751.2023.2261566
work_keys_str_mv AT zitengliang developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT xiwu developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT jiajingwu developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT shuoliu developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT jinchengtong developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT taoli developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT yuanlingyu developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT lizhang developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT chenyanzhao developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT qionglu developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT haiyangqin developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT jianhuinie developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT weijinhuang developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector
AT youchunwang developmentofanautomatedhighthroughputsarscov2neutralizationassaybasedonapseudotypedvirususingavesicularstomatitisvirusvsvvector